Novartis\' CART therapy Kymriah gets NICE green light in diffuse large Bcell lymphoma

Novartis' CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

05:47 EST 1 Feb 2019 | Pharmafile

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell (CAR-T) therapy Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell forms of the condition (DLBCL) who have not responded or have relapsed after two courses of chemotherapy.

It is estimated that 200 patients will be eligible to access the treatment each year in England and Wales.

read more

More From BioPortfolio on "Novartis' CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma"